NetworkNewsBreaks Archive - Page 467 of 2291

MondaySep 23, 2024 11:20 am

NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation at the 24th Annual Biotech in Europe Forum

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that CEO John Climaco will present at the 24th Annual Biotech in Europe Forum. The presentation is scheduled for Wednesday, September 25, 2024, at 1:55 p.m. CEST in Basel, Switzerland. Additionally, management will participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. To view the full press release, visit https://nnw.fm/tantX About CNS Pharmaceuticals Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing…

MondaySep 23, 2024 10:45 am

NetworkNewsBreaks – TC Biopharm (Holdings) PLC (NASDAQ: TCBP) Completes ACHIEVE Trial Full-Dose Regimen for First Patient

TC Biopharm (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, has announced a key step in its ACHIEVE clinical trial. According to the announcement, the first patient has completed the full-dose regimen in the phase 2b trial. In addition, the company announced that six patients have received a second dose and three patients have received a third dose; patients can receive up to four total doses of TCB under the trial protocol. Furthermore, no TCB008-related adverse events have been observed in any of the restart patients. To view the full press release, visit…

MondaySep 23, 2024 10:44 am

NetworkNewsBreaks – Dynasty Gold Corp.’s (TSX.V: DYG) (FSE: D5G1) (OTC: DGDCF) Initial Assay Results from 2024 Drill Program Demonstrate ‘Richness of the Gold System’ at Thundercloud

Dynasty Gold (TSX.V: DYG) (FSE: D5G1) (OTC: DGDCF), a Canadian mineral exploration company, today announced assay results for the first phase of the 2024 drill program at its Thundercloud property. The program comprises 2,198 meters. According to the announcement, drilling successfully intersected high-grade gold mineralization of 5.13 g/t Au over 18 meters from 97.5m to 115.5m, including 9.3 g/t Au over 4.5 meters and numerous 5 to 8+ g/t Au over 1.5m in drillhole TC24-02 (30 meters additional assay results are pending). In addition, drilling intersected broad zones of lower grade mineralization from 25 meters below surface with intercepts between…

MondaySep 23, 2024 10:08 am

NetworkNewsBreaks – Gaxos.ai Inc. (NASDAQ: GXAI) Enters into $3.24M Definitive Agreement

Gaxos.ai Inc. (NASDAQ: GXAI), a company developing artificial intelligence applications across various sectors, has entered into a definitive agreement for the exercise of certain existing warrants. The agreement outlines the purchase of 1,256,734 shares of certain of its common stock at a reduced exercise price of $2.58 per share. According to the announcement, the offering is expected to close today, subject to closing conditions. The company plans to use funds from the offering, which is anticipated to total an estimated $3.24 million before standard deductions and fees, for working capital and other general corporate purposes. H.C. Wainwright & Co. is…

MondaySep 23, 2024 8:30 am

NetworkNewsBreaks – D-Wave Quantum Inc. (NYSE: QBTS) Announces Partnership with Staque to Accelerate Commercial Adoption of Quantum in the Middle East

D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software and services, and the world’s first commercial supplier of quantum computers, has announced its partnership with Staque, a leading consulting and development practice with a focus on artificial intelligence (“AI”), blockchain and quantum computing. According to the announcement, the two companies will work to“foster collaboration and usage of quantum computing solutions for optimization and AI applications.” The companies aim to accelerate the commercial adoption of annealing quantum computing across the Middle East. “We believe organizations must embrace today’s advanced technologies such as quantum computing and AI in…

MondaySep 23, 2024 8:30 am

NetworkNewsBreaks – AROYA Sponsors, Exhibits at Hall of Flowers Event, Open to the Public for First Time

AROYA, the leading cannabis cultivation platform, is a sponsor of the Hall of Flowers event in California and is exhibiting its state-of-the-art precision irrigation and cultivation technology at the event. The Hall of Flowers Market & Festival is slated for Sept. 21, 2024, in Sonoma, California, and is open to the public for the first time ever. According to the announcement, the company will have special product drops and offer exclusive deals for attendees, who will also be able to participate in demonstrations of the AROYA GO unit and interact with expert AROYA team members at the AROYA exhibit booth.…

FridaySep 20, 2024 3:36 pm

NetworkNewsBreaks – McEwen Mining Inc. (NYSE: MUX) (TSX: MUX) Featured by Rocks And Stocks

McEwen Mining (NYSE: MUX) (TSX: MUX), an asset rich diversified gold and silver producer in the Americas with a large exposure to copper through its McEwen Copper subsidiary, continues to capture attention throughout the mining space. Allan Barry Laboucan, founder of Rock And Stocks, covered the company in a recent video report posted on YouTube. “This report opens on the action in gold trading, followed by a deep dive into the gold exploration potential at McEwen Mining,” he wrote to his subscribers. “Hidden in plain sight for anybody to see is the spectacular exploration potential at McEwen Mining's gold mining…

FridaySep 20, 2024 3:30 pm

NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating ‘More Effective, Tolerable’ Oral Delivery of GLP-1 Drugs

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, looks to offer a better alternative to diabetes management and treatment through its patented DehydraTECH(TM) technology. “Lexaria has recently made strides with glucagon-like peptide-1 (‘GLP-1’) studies. It has reported positive interim results from an animal study on diabetes. This milestone best showcases the potential of its patented technology in not only addressing diabetes and obesity. Recently, the company announced the dosing completion of its human pilot study #2, GLP-1-H24-2, which sought to explore effective oral delivery of GLP-1 drugs. Some evaluated aspects included side effects, blood levels of…

FridaySep 20, 2024 3:02 pm

NetworkNewsBreaks – Verb Technology Company Inc. (NASDAQ: VERB) Unveils ‘GO FUND YOURSELF!’ Interactive Social Crowdfunding Platform

Verb Technology Company Inc. (NASDAQ: VERB) has launched its new interactive social crowdfunding platform, GO FUND YOURSELF!, designed for public and private companies to present Regulation CF and Regulation A offerings while engaging a global investor audience. The platform allows real-time investment through VERB’s MARKET.live and features high-profile guest Titans like UFC fighter Michael Chandler and actor James Maslow. The show spotlights innovative companies, including GolfLync, a social platform blending golf with matchmaking elements, alongside other issuers in diverse sectors. The platform generates revenue from company fees, product sales, and sponsorships. “Our goal is to democratize the investment process, allowing…

FridaySep 20, 2024 2:30 pm

NetworkNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Stands Distinct from Industry Players with Buntanetap

Annovis Bio (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, secured U.S. patent No. 12,042,482 covering methods for treating traumatic brain injury (“TBI”) and nerve injury with buntanetap, the company’s lead drug candidate. “Buntanetap (formerly Posiphen) targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins such as amyloid beta, tau, alpha-synuclein, and TDP43; by inhibiting their translation, the drug improves synaptic transmission, axonal transport, reduces neuroinflammation, and prevents nerve cells from dying. Unlike monoclonal antibody therapies, buntanetap is an orally available small molecule that inhibits multiple neurotoxic proteins simultaneously, making it a promising solution…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

NetworkNewsBreaks